EP4058148

AMGEN
Application Number
EP20729951A
Filing Date
May 8, 2020
Status
Granted And Under Opposition
Feb 9, 2024
Grant Date
Mar 13, 2024
External Links
Slate, Register

Biblio Summary

The patent EP4058148B1 was granted on Mar 13, 2024 by Amgen The patent is currently Granted And Under Opposition.

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

REGENERON PHARMACEUTICALS, INC.Aug 2, 2024 N.A.
STRAWMAN LIMITEDMar 15, 2024 N.A.

The table below shows the patents of Amgen that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP4209499Charged Depth Filtration Of Antigen-Binding ProteinsAug 7, 20241
EP3819007Dosing Regimen For Anti-Bcma AgentsJul 10, 20244
EP2637670Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsMar 13, 20244